On 26 April 2023, the European Commission (the
“Commission”) adopted a proposal for a new Directive
and Regulation (the “Proposal”) which revise and
replace the existing general pharmaceutical legislation.
The proposal adopted by the Commission replaces the existing
general pharmaceutical legislation (Regulation 726/2004 and
Directive 2001/83/EC) and the legislation on pharmaceuticals for
children and rare diseases (Regulation 1901/2006 and Regulation
141/2000/EC respectively).
In the Commission's press release on the Proposal, it was
stated that the pharmaceuticals authorized in the EU are still not
reaching patients fast enough and are not equally accessible across
all Member States. The proposal aims to prevent pharmaceutical
shortages and unmet medical needs due to high pricing of innovative
treatments. In addition to addressing public health from a
pharmaceutical access viewpoint, the proposal aims to adapt the
rules to new technologies, reduce bureaucracy,